RxDoctor Payments Data

Tammy Word, APRN

Psychiatric/Mental Health · Grand Rapids, MNNPI 1548861016

Payments from drug & device makers

$270in general payments, 2019–2025

Across 17 payments — averaging $15.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$70
  • Teva Pharmaceuticals USA, Inc.$33
  • Neurocrine Biosciences, Inc.$32
  • Johnson & Johnson$31
  • Otsuka America Pharmaceutical, Inc.$28
  • Axsome Therapeutics, Inc.$18
  • plus $58 from 4 others

What the payments were for

  • Food & beverage$270100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$270 in reported general payments places this provider in the 80th percentile of 407 psychiatric/mental health providers in Minnesota.

See all psychiatric/mental health providers in Minnesota

Medicare billing

Part B allowed, 2024
$27,108
Medicare patients
52
Services billed
297

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate36$289,966
Invega SustennaPaliperidone Palmitate24$80,084
VraylarCariprazine Hcl45$65,628
RexultiBrexpiprazole29$42,288
Risperdal ConstaRisperidone Microspheres12$30,601
BelsomraSuvorexant45$19,929
VyvanseLisdexamfetamine Dimesylate43$18,240
Lurasidone Hcl38$16,846
TrintellixVortioxetine Hydrobromide30$14,701
Lisdexamfetamine Dimesylate58$11,994
Aripiprazole148$7,810
Asenapine Maleate26$5,986
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl21$5,697
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine74$5,036
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine176$4,897

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$32$289,96636 claims
Johnson & JohnsonInvega Sustenna, Risperdal Consta$31$110,68536 claims
Otsuka America Pharmaceutical, Inc.Rexulti$28$42,28829 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 407 psychiatric/mental health providers in Minnesota.

Other psychiatric/mental health in Grand Rapids

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →